# Ascorbate in Myelodysplastic Syndrome

> **NCT07283900** · PHASE2 · RECRUITING · sponsor: **Prajwal Dhakal** · enrollment: 38 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** High-dose ascorbate
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT07283900
- **Lead sponsor:** Prajwal Dhakal
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-11
- **Primary completion:** 2028-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07283900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07283900, "Ascorbate in Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT07283900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*